Author

Baris Gencer

Cardiology Division, Geneva University Hopsitals - Cited by 17,299 - Cardiology - Lipids - Clinical Research

Biography

Dr.  Baris Gencer is currently working in Cardiology Division, Department of Medicine, Geneva University Hospital, Switzerland. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work. 
Title
Cited by
Year
Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by …
AP Carnicelli, H Hong, SJ Connolly, J Eikelboom, RP Giugliano, ...Circulation 145 (4), 242-255, 2022202
73
2022
Effect of long-term marine ɷ-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review …
B Gencer, L Djousse, OT Al-Ramady, NR Cook, JAE Manson, CM AlbertCirculation 144 (25), 1981-1990, 2021202
52
2021
Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease
ML O’Donoghue, RS Rosenson, B Gencer, JAG López, NE Lepor, ...New England Journal of Medicine 387 (20), 1855-1864, 2022202
48
2022
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome
B Gencer, DA Morrow, E Braunwald, EL Goodrich, M Hilvo, D Kauhanen, ...European Journal of Preventive Cardiology 29 (6), 895-902, 2022202
17
2022
European society of cardiology quality indicators for cardiovascular disease prevention: developed by the working group for cardiovascular disease prevention quality indicators …
S Aktaa, B Gencer, E Arbelo, CH Davos, I Désormais, M Hollander, ...European journal of preventive cardiology 29 (7), 1060-1071, 2022202
16
2022
Challenges in the management of atrial fibrillation with subclinical hyperthyroidism
B Gencer, AR Cappola, N Rodondi, TH ColletFrontiers in endocrinology 12, 95492, 2022202
7
2022
Sex differences in atrial fibrillation risk: the VITAL Rhythm Study
HK Siddiqi, M Vinayagamoorthy, B Gencer, C Ng, J Pester, NR Cook, ...JAMA cardiology 7 (10), 1027-103, 2022202
5
2022
Clinical safety outcomes in relation to lipoprotein (a) concentration: insights from the FOURIER trial
B Gencer, RP Giugliano, M Tang, F Mach, ES Stroes, I Gouni-berthold, ...Circulation 1 (Suppl_1), A1103-A1103, 2021202
4
2021
European Society of Cardiology quality indicators for the cardiovascular pre-operative assessment and management of patients considered for non-cardiac surgery. Developed in …
B Gencer, CP Gale, S Aktaa, S Halvorsen, B Beska, M Abdelhamid, ...European Heart Journal-Quality of Care and Clinical Outcomes 9 (4), 1-41, 20220
3
2023
Cysteine‐rich angiogenic inducer 61 improves prognostic accuracy of GRACE (global registry of acute coronary events) 2.0 risk score in patients with acute coronary syndromes
R Klingenberg, S Aghlmandi, L Räber, A Akhmedov, B Gencer, ...Journal of the American Heart Association 10 (20), e020488, 2021202
3
2021
Lipid‐Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta‐Analysis of Exclusion Criteria
M Aeschbacher‐Germann, N Kaiser, A Speierer, MR Blum, DC Bauer, ...Journal of the American Heart Association 12 (1), e026551, 20220
3
2023
History of peripheral artery disease and cardiovascular risk of real-world patients with acute coronary syndrome: Role of inflammation and comorbidities
A Denegri, G Magnani, S Kraler, F Bruno, R Klingenberg, F Mach, ...International journal of cardiology 82, 76-82, 20220
3
2023
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups
B Gencer, A Eisen, D Berger, F Nordio, SA Murphy, LT Grip, C Chen, ...American Heart Journal 47, 4-3, 0
2
2022
Smoking cessation in people with and without diabetes after acute coronary syndrome
L Clement, B Gencer, O Muller, R Klingenberg, L Räber, CM Matter, ...Nicotine and Tobacco Research 5 (1), 58-65, 030
2
2023
Polypharmacie et medicaments inappropriés chez les patients âgés multimorbides-Ce que l’étude OPERAM nous apprend et va nous apprendre [Polypharmacy and inappropriate …
L Bretagne, K Tabea Jungo, MR Blum, M Schwenkglenks, A Chiolero, ...Rev Med Suisse 18 (77), 47-43, 0
2
2022
Inclisiran in primary prevention: reality or fiction?
B Gencer, F MachEuropean heart journal 43 (48), 5058-5060, 2022202
1
2022
2022 Saudi guidelines for the management of dyslipidemia
J AlRahimi, S AlSaif, M Alasnag, Z Awan, F Almutairi, H Al Mudaiheem, ...Heart Views: The Official Journal of the Gulf Heart Association 24 (2), 67, 2023202
1
2023

Referred From: https://scholar.google.com/citations?hl=en&user=lZblAGIAAAAJ

Cited by
Citations 17299
h-index 38
i10-index 78
Recommended Journals
Open Access Journals